The present invention relates to therapeutic immunomodulating compounds capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also encompasses the use of the said therapeutic compounds and their derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.